Palvella Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-11.1%projected annual EPS growth
Analyst Coverage
15analysts covering
FY EPS (est.)
-$6.37next fiscal year
Monitoring Framework
Key Performance Indicators
QTORIN Rapamycin Phase 3 SELVA mLM-IGA Mean Improvement Annually2.1Target: Statistically significant improvement (p<0.001)
Pro Forma Cash and Cash Equivalents Quarterly274MTarget: Sufficient capital to fund late-stage development and launch preparation
Research and Development Expenses Annually22.8MTarget: Efficient allocation of capital to advance clinical pipeline
Watch Items
- New Drug Application (NDA) Submission for QTORIN Rapamycin in Microcystic Lymphatic MalformationsTrigger: Submission timeline target of 2H 2026Action: Monitor regulatory filings and FDA communications following the completed pre-NDA meeting
- Potential FDA Approval and U.S. Commercial Launch of QTORIN RapamycinTrigger: Target approval timeline of 1H 2027Action: Track FDA decision milestones and commercial readiness activities
- Pipeline Expansion of QTORIN Rapamycin and QTORIN PitavastatinTrigger: Initiation of Phase 2/3 trials in 2H 2026Action: Monitor clinical trial registrations and patient enrollment updates for cutaneous venous malformations, clinically significant angiokeratomas, and disseminated superficial actinic porokeratosis
Research as of 19 Jun 2026